NCCN Updates Breast Cancer and Ovarian Cancer Treatment Guidelines with New Maintenance Therapy and Immunotherapy Recommendations
Key Insights
The National Comprehensive Cancer Network (NCCN (search)) has released updated guidelines for breast cancer (Version 4.2025) and ovarian cancer (Version 3.2025) with significant changes to treatment protocols and maintenance therapy recommendations.
Key breast cancer updates include expanded immunotherapy integration with pembrolizumab for triple-negative breast cancer, revised febrile neutropenia risk classifications, and new flexibility in anthracycline-taxane sequencing.
The ovarian cancer guidelines now recommend niraparib monotherapy as maintenance treatment for BRCA1 (search)/2 wild-type patients with homologous recombination deficiency who did not receive bevacizumab during primary therapy.
The National Comprehensive Cancer Network (NCCN (search)) has released significant updates to its clinical practice guidelines for both breast cancer and ovarian cancer, introducing important changes that will impact treatment protocols and maintenance therapy strategies for oncology professionals.
Breast Cancer Guidelines Expand Immunotherapy Integration
The NCCN (search) Clinical Practice Guidelines for Breast Cancer Version 4.2025, released on April 30, 2025, introduces substantial modifications to treatment protocols, particularly emphasizing the integration of immunotherapy in early-stage triple-negative breast cancer. Key updates involve treatment indications for olaparib and capecitabine, as well as combination regimens that include carboplatin, paclitaxel, cyclophosphamide, anthracyclines (doxorubicin or epirubicin), and pembrolizumab for both neoadjuvant and adjuvant settings.
The guidelines now provide greater clinical flexibility in the administration sequence of anthracycline- and taxane-based regimens. It is now explicitly acceptable to administer taxane-containing components prior to anthracycline-based therapy in certain settings, supported by data suggesting comparable efficacy and potentially improved tolerability or logistical planning.
Revised Risk Classifications and Safety Monitoring
The risk classification for febrile neutropenia has been revised for select multi-agent regimens involving immunotherapy, highlighting the importance of appropriate prophylaxis and monitoring strategies. This change reflects the growing integration of immunotherapy agents and the need for precise regimen sequencing and patient selection.
Updates have also been made to drug-specific information for several commonly used agents, including ado-trastuzumab emtansine, carboplatin, docetaxel, leuprolide acetate, paclitaxel, pembrolizumab, pertuzumab, and trastuzumab, including its subcutaneous formulations. These changes span guidance on supportive care, safety monitoring, dose holds, and special administration instructions.
Ovarian Cancer Guidelines Refine Maintenance Therapy Approach
The NCCN (search) Guidelines for ovarian cancer Version 3.2025 introduces a significant modification to maintenance therapy recommendations in section OV-5. For patients with BRCA1 (search)/2 wild-type or unknown status who did not receive bevacizumab during primary therapy and are identified as homologous recombination (HR) deficient, the recommended maintenance therapy has been modified to include niraparib monotherapy.
This adjustment underscores the growing emphasis on tailoring maintenance therapy based on molecular characteristics beyond BRCA mutation status alone. The update specifically targets patients with epithelial ovarian, fallopian tube, or primary peritoneal cancers, reflecting a more nuanced approach to personalized treatment selection.
Clinical Implementation and Pharmacy Practice Impact
These guideline updates have significant implications for oncology pharmacy professionals, particularly in areas such as regimen selection, sequencing, febrile neutropenia risk assessment, and supportive care management. Oncology pharmacists are essential in ensuring the successful implementation of updated treatment strategies, including the use of niraparib in HR-deficient ovarian cancer.
Pharmacy professionals must carefully review patients' HR deficiency testing results to guide treatment selection and ensure appropriate monitoring for PARP inhibitor-associated toxicities, including hematologic adverse effects. Their expertise in interpreting genetic and HRD testing results, educating patients and providers, managing oral maintenance therapies, and collaborating with multidisciplinary teams enables personalized, evidence-based care that aligns with evolving clinical guidelines.
The updates reinforce the pharmacist's role in ensuring treatment safety and optimization, emphasizing the need to assess risks within the context of patient-specific factors and institutional protocols. Pharmacy professionals are encouraged to review these guideline updates in full to align clinical practice with the latest evidence-based recommendations and maintain best practices in cancer pharmacotherapy.